Alnylam Pharmaceuticals, Inc. (ALNY) vs Royal Caribbean Cruises Ltd. (RCL)
A side-by-side comparison of Alnylam Pharmaceuticals, Inc. and Royal Caribbean Cruises Ltd. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 13, 2026. Differences are shown without an overall score or investment verdict.
Different business models: ALNY is classified in Healthcare; RCL is classified in Consumer Cyclical. Margin, capital intensity, and valuation differences should be interpreted in that sector context.
ALNY
Alnylam Pharmaceuticals, Inc.
$248.68HealthcareDelayed quote: Sep 11, 2026, 4:00 PM EDT
RCL
Royal Caribbean Cruises Ltd.
$260.14Consumer CyclicalDelayed quote: Sep 11, 2026, 4:00 PM EDT
Total return — ALNY vs RCL
growth of $100 · dividends reinvested · last 10yALNY +247.1% (+13.3%/yr)RCL +323.5% (+15.5%/yr)RCL compounded faster over this window
ALNY RCL
ALNY vs RCL: by the numbers
- •RCL is the larger company ($69.77B vs $33.28B market cap).
- •RCL trades at the lower trailing earnings multiple (16.08 vs 42.01 P/E), one valuation lens rather than an overall verdict.
- •RCL converts more revenue to profit (23.56% vs 16.82% net margin).
- •RCL grew revenue faster over the past five years (188.60% vs 47.53% CAGR).
- •RCL pays a dividend (1.92% yield), while ALNY has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | ALNY | RCL |
|---|---|---|
| P/E ratio | 42.01 | 16.08 |
| Forward P/E | 37.26 | 14.65 |
| P/S ratio | 6.93 | 3.73 |
| P/B ratio | 24.57 | 6.82 |
| EV / EBITDA | 31.15 | 13.56 |
| FCF yield | 1.63% | N/A |
Profitability
| Metric | ALNY | RCL |
|---|---|---|
| Gross margin | 79.72% | 46.64% |
| Operating margin | 20.81% | 27.32% |
| Net margin | 16.82% | 23.56% |
| ROE | 59.67% | 43.01% |
| ROIC | 24.71% | 14.59% |
Dividends
| Metric | ALNY | RCL |
|---|---|---|
| Dividend yield | N/A | 1.92% |
| Payout ratio | N/A | 30.90% |
Growth (annualized)
| Metric | ALNY | RCL |
|---|---|---|
| Revenue CAGR (5Y) | 47.53% | 188.60% |
| EPS CAGR (5Y) | N/A | 9.81% |
| FCF CAGR (5Y) | N/A | 11.57% |
| Total return CAGR (5Y) | 5.58% | 26.76% |
Frequently asked
- Which has the lower trailing P/E, ALNY or RCL?
- RCL has the lower trailing P/E: ALNY trades at 42.01 and RCL at 16.08. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, ALNY or RCL?
- Over the past five years, RCL grew revenue faster — ALNY at a 47.53% CAGR versus RCL at 188.60%.
- Does ALNY or RCL pay a bigger dividend?
- RCL pays a dividend (1.92% yield), while ALNY has no payments in the available dividend history.
- Is ALNY or RCL more profitable?
- RCL runs the higher net margin — ALNY at 16.82% versus RCL at 23.56%.
- How have ALNY and RCL total returns compared?
- Over the past 10 years, ALNY delivered 13.54% and RCL delivered 16.06% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Alnylam Pharmaceuticals P/E ratioRoyal Caribbean Cruises P/E ratioRoyal Caribbean Cruises dividend yieldAlnylam Pharmaceuticals ROERoyal Caribbean Cruises ROEAlnylam Pharmaceuticals operating marginRoyal Caribbean Cruises operating marginAlnylam Pharmaceuticals revenue growthRoyal Caribbean Cruises revenue growthAlnylam Pharmaceuticals free cash flowRoyal Caribbean Cruises free cash flow
Alnylam Pharmaceuticals & Royal Caribbean Cruises appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 13, 2026.